Drug Patents owned by Indivior Inc

1. Drug name - PERSERIS KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10406160 INDIVIOR INC Sustained release small molecule drug formulation Jun, 2026

(3 years from now)

US9597402 INDIVIOR INC Sustained release small molecule drug formulation Sep, 2026

(3 years from now)

US10058554 INDIVIOR INC Sustained release small molecule drug formulation Sep, 2026

(3 years from now)

US11110093 INDIVIOR INC Sustained release small molecule drug formulation Nov, 2026

(4 years from now)

US9186413 INDIVIOR INC Sustained delivery formulations of risperidone compounds Feb, 2028

(5 years from now)

US10376590 INDIVIOR INC Sustained delivery formulations of risperidone compound Feb, 2028

(5 years from now)

US11013809 INDIVIOR INC Sustained delivery formulations of risperidone compound Feb, 2028

(5 years from now)

US10010612 INDIVIOR INC Sustained delivery formulations of risperidone compounds Feb, 2028

(5 years from now)

US9180197 INDIVIOR INC Sustained delivery formulations of risperidone compounds Feb, 2028

(5 years from now)

Drugs and Companies using RISPERIDONE ingredient

Treatment: Method of treating schizophrenia; Administration of risperidone; Treating schizophrenia; Treatment of schizophrenia

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
90MG FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Prescription
120MG FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Prescription

2. Drug name - SUBLOCADE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9272044 INDIVIOR INC Injectable flowable composition buprenorphine Jun, 2031

(8 years from now)

US9498432 INDIVIOR INC Injectable flowable composition comprising buprenorphine Jun, 2031

(8 years from now)

US10198218 INDIVIOR INC Injectable flowable composition comprising buprenorphine Jun, 2031

(8 years from now)

US10592168 INDIVIOR INC Injectable flowable composition comprising buprenorphine Jun, 2031

(8 years from now)

US9827241 INDIVIOR INC Injectable flowable composition comprising buprenorphine Jun, 2031

(8 years from now)

US9782402 INDIVIOR INC Injectable composition comprising buprenorphine Jun, 2031

(8 years from now)

US10558394 INDIVIOR INC Injectable flowable composition comprising buprenorphine Jun, 2031

(8 years from now)

US8975270 INDIVIOR INC Injectable flowable composition comprising buprenorphine Sep, 2031

(8 years from now)

US8921387 INDIVIOR INC Injectable flowable composition comprising buprenorphine Jan, 2032

(9 years from now)

US11000520 INDIVIOR INC Buprenorphine dosing regimens Nov, 2035

(13 years from now)

US10646484 INDIVIOR INC Methods to treat opioid use disorder Jun, 2038

(15 years from now)

Drugs and Companies using BUPRENORPHINE ingredient

Treatment: Treating opioid addiction by administering buprenorphine; treating opioid addiction by administering buprenorphine once per month; treating opioid addiction by administering buprenorphine composition with 28 day dose duration; treating opioid addiction by subcutaneous injection of buprenorphine; In situ formation of solid buprenorphine composition; Treatment of moderate to severe opioid use disorder; Treating opioid dependency by administering buprenorphine; treating opioid addiction by administration of buprenorphine; treating opioid dependency by subcutaneously administering buprenorphine; treating opioid addiction by 100 mg or 300 mg dose buprenorphine; treating opioid dependency by administering buprenorphine once per month; Treating addiction with 100 mg or 300 mg dose of buprenorphine; treating opioid addiction by administering buprenorphine; treating addiction by once per month administration of buprenorphine; treating addiction by subcutaneous injection of buprenorphine; Treating opioid dependency by administering buprenorphine; treating opioid dependency by administering buprenorphine once monthly; Treating opioid dependency by administering buprenorphine once per month; treating opioid dependence by administering buprenorphine; Treating opioid use disorder

Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
100MG/0.5ML (100MG/0.5ML) SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS Prescription
300MG/1.5ML (200MG/ML) SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS Prescription

3. Drug name - SUBOXONE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10285910 INDIVIOR INC Sublingual and buccal film compositions Oct, 2022

(8 days from now)

US8017150 INDIVIOR INC Polyethylene oxide-based films and drug delivery systems made therefrom Feb, 2023

(4 months from now)

US8603514 INDIVIOR INC Uniform films for rapid dissolve dosage form incorporating taste-masking compositions Apr, 2024

(1 year, 6 months from now)

US11135216 INDIVIOR INC Sublingual and buccal film compositions Aug, 2029

(6 years from now)

US9687454 INDIVIOR INC Sublingual and buccal film compositions Aug, 2029

(6 years from now)

US8475832 INDIVIOR INC Sublingual and buccal film compositions Mar, 2030

(7 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Treatment: Treatment of opioid dependence/sublingual or buccal application; Treating opioid use disorder; This drug is administered by sublingual route to humans for maintenance treatment of opioid dependence

Dosage: FILM;BUCCAL, SUBLINGUAL

More Information on Dosage
Strength Dosage Availability
EQ 2MG BASE;EQ 0.5MG BASE FILM;BUCCAL, SUBLINGUAL Prescription
EQ 4MG BASE;EQ 1MG BASE FILM;BUCCAL, SUBLINGUAL Prescription
EQ 8MG BASE;EQ 2MG BASE FILM;BUCCAL, SUBLINGUAL Prescription
EQ 12MG BASE;EQ 3MG BASE FILM;BUCCAL, SUBLINGUAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.